# Ototoxicity and Hearing Loss

Ototoxicity refers to damage to the inner ear caused by certain medications or chemicals, potentially resulting in hearing loss, tinnitus (ringing in the ears), or balance disorders. Some medications used to treat serious medical conditions, including certain antibiotics, chemotherapy drugs, and other therapies, may carry a risk of ototoxic effects.

Understanding these risks, recognizing early warning signs, and monitoring changes in hearing are important steps in protecting hearing health. Early identification and appropriate intervention can help patients and healthcare professionals make informed decisions about treatment and hearing care.

Explore the resources below for educational materials, research, clinical guidance, and information on the prevention, identification, and management of ototoxicity-related hearing loss.

## Resources

- [NCODA/ADA Ototoxicity Screening Policy and Procedure](https://audiologist.org/_resources/documents/ototoxicity/NCODA-ADA-Ototoxicity-Screening.pdf)
- [Hearing and Balance Questionnaire](https://audiologist.org/_resources/documents/ototoxicity/Hearing-and-Balance-Questionnaire.pdf)
- [Linking Oncology and Audiology - Collaborative Care for Cisplatin Ototoxicity](https://vimeo.com/1237601578/fb8bc4cc25)

## Cisplatin and Carboplatin Ototoxicity: Reference List

**Reviews and Burden of Disease**

- Brock, P. R. (2022). New insights into cisplatin ototoxicity. *Cancer, 128*(1), 43–46. <https://doi.org/10.1002/cncr.33847>
- Editorial accompanying Meijer et al. on very young children (commentary, not primary research). PMID [34490622](https://pubmed.ncbi.nlm.nih.gov/34490622/)
- Chattaraj, A., Syed, M. P., Low, C. A., & Owonikoko, T. K. (2023). Cisplatin-induced ototoxicity: A concise review of the burden, prevention, and interception strategies. *JCO Oncology Practice, 19*(5), 278–283. <https://doi.org/10.1200/OP.22.00710>
- Concise review of burden, prevention, and interception strategies, with emphasis on gaps in adult monitoring guidance. PMID [36921239](https://pubmed.ncbi.nlm.nih.gov/36921239/) · [PMC10414722](https://pmc.ncbi.nlm.nih.gov/articles/PMC10414722/)
- Dillard, L. K., Lopez-Perez, L., Martinez, R. X., Fullerton, A. M., Chadha, S., & McMahon, C. M. (2022). Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis. *Cancer Epidemiology, 79*, Article 102203. <https://doi.org/10.1016/j.canep.2022.102203>
- Systematic review and meta-analysis estimating global prevalence of platinum-associated ototoxic hearing loss. PMID [35724557](https://pubmed.ncbi.nlm.nih.gov/35724557/) · [PMC9339659](https://pmc.ncbi.nlm.nih.gov/articles/PMC9339659/)
- Janowiak-Majeranowska, A., Abdulaziz-Opiela, G., Osowski, J., & Mikaszewski, B. (2024). Prevalence of platinum-induced ototoxicity among patients suffering from hematological malignancies - a systematic review. *Contemporary Oncology, 28*(2), 98–104. <https://doi.org/10.5114/wo.2024.141774>
- Systematic review of platinum ototoxicity prevalence in hematologic malignancies. PMID [39421713](https://pubmed.ncbi.nlm.nih.gov/39421713/) · [PMC11480915](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480915/)
- Mirabile, A., Vukatana, A., Guizzardi, M., Vaccarello, G., Giordano, L., & Addeo, R. (2026). Cisplatin-induced ototoxicity in head and neck cancer: A systematic review of current evidence, clinical implications, and the need for standardized monitoring. *Current Oncology, 33*(10), Article 584. <https://doi.org/10.3390/curroncol33100584>
- Systematic review of cisplatin ototoxicity in head and neck cancer; compares dosing schedules and calls for standardized monitoring. PMID [42930151](https://pubmed.ncbi.nlm.nih.gov/42930151/) · [PMC13703248](https://pmc.ncbi.nlm.nih.gov/articles/PMC13703248/)
- Oh, H., & Park, M. K. (2025). Assessment and management of chemotherapy-induced ototoxicity in children. *Journal of Audiology & Otology, 29*(2), 79–85. <https://doi.org/10.7874/jao.2025.00073>
- Review of pediatric assessment and management of chemotherapy-induced ototoxicity. PMID [40296470](https://pubmed.ncbi.nlm.nih.gov/40296470/) · [PMC12046201](https://pmc.ncbi.nlm.nih.gov/articles/PMC12046201/)
- Patatt, F. S. A., Gonçalves, L. F., Paiva, K. M., & Haas, P. (2022). Ototoxic effects of antineoplastic drugs: A systematic review. *Brazilian Journal of Otorhinolaryngology, 88*(1), 130–140. <https://doi.org/10.1016/j.bjorl.2021.02.008>
- Systematic review of hearing changes after platinum antineoplastics; cisplatin more ototoxic than carboplatin. PMID [33757754](https://pubmed.ncbi.nlm.nih.gov/33757754/) · [PMC9422719](https://pmc.ncbi.nlm.nih.gov/articles/PMC9422719/)
- Phillips, O. R., Baguley, D. M., Pearson, S. E., & Akeroyd, M. A. (2023). The long-term impacts of hearing loss, tinnitus and poor balance on the quality of life of people living with and beyond cancer after platinum-based chemotherapy: A literature review. *Journal of Cancer Survivorship, 17*(1), 40–58. <https://doi.org/10.1007/s11764-022-01314-9>
- Literature review on long-term quality-of-life impacts of hearing loss, tinnitus, and imbalance after platinum chemotherapy. PMID [36637633](https://pubmed.ncbi.nlm.nih.gov/36637633/) · [PMC9971148](https://pmc.ncbi.nlm.nih.gov/articles/PMC9971148/)
- Romano, A., Attinà, G., Maurizi, P., Talloa, D., Mastrangelo, S., & Ruggiero, A. (2025). Platinum-induced ototoxicity and hearing impairment in children and adolescents. *Drugs in Context, 14*, Article 2025-3-1. <https://doi.org/10.7573/dic.2025-3-1>
- Narrative review of cisplatin/carboplatin ototoxicity in pediatric patients. PMID [40524783](https://pubmed.ncbi.nlm.nih.gov/40524783/) · [PMC12169122](https://pmc.ncbi.nlm.nih.gov/articles/PMC12169122/)
- Wojno, A., Cichy, O., Wojno, A., Dorobisz, K., & Pazdro-Zastawny, K. (2026). Ototoxicity associated with antineoplastic agents in the pediatric population: An evidence-based review of auditory monitoring strategies and contemporary diagnostic frameworks—Narrative review. *Diagnostics, 16*(9), Article 1272. <https://doi.org/10.3390/diagnostics16091272>
- Narrative review of pediatric auditory monitoring strategies and diagnostic frameworks. PMID [42121973](https://pubmed.ncbi.nlm.nih.gov/42121973/) · [PMC13162660](https://pmc.ncbi.nlm.nih.gov/articles/PMC13162660/)

**Mechanisms and Cochlear Retention**

- Li, Y., Zhang, T., Song, Q., Gao, D., Li, Y., Jie, H., Huang, P., Zheng, G., Yang, J., & He, J. (2023). Cisplatin ototoxicity mechanism and antagonistic intervention strategy: A scope review. *Frontiers in Cellular Neuroscience, 17*, Article 1197051. <https://doi.org/10.3389/fncel.2023.1197051>
- Scoping review of cisplatin ototoxicity mechanisms and candidate protective interventions. PMID [37323582](https://pubmed.ncbi.nlm.nih.gov/37323582/) · [PMC10267334](https://pmc.ncbi.nlm.nih.gov/articles/PMC10267334/)
- Rose, O., Croonenberg, T., Clemens, S., Hinteregger, T., Eppacher, S., Huber-Cantonati, P., Garcia-Miralles, M., Liuni, R., & Dossena, S. (2024). Cisplatin-induced hearing loss, oxidative stress, and antioxidants as a therapeutic strategy—A state-of-the-art review. *Antioxidants, 13*(12), Article 1578. <https://doi.org/10.3390/antiox13121578>
- State-of-the-art review of oxidative stress and antioxidant otoprotection. PMID [39765905](https://pubmed.ncbi.nlm.nih.gov/39765905/) · [PMC11673797](https://pmc.ncbi.nlm.nih.gov/articles/PMC11673797/)
- Ruggiero, A., Picciotti, P. M., Mastrangelo, S., Romano, A., Talloa, D., Galli, J., & Attinà, G. (2026). Progressive sensorineural hearing loss following cisplatin chemotherapy: Mechanisms underlying cochlear retention and long-term ototoxicity. *Pharmaceuticals, 19*(5), Article 779. <https://doi.org/10.3390/ph19050779>
- Review of cochlear platinum retention and progressive long-term hearing loss. PMID [42198452](https://pubmed.ncbi.nlm.nih.gov/42198452/) · [PMC13210263](https://pmc.ncbi.nlm.nih.gov/articles/PMC13210263/)
- Tan, W. J. T., & Vlajkovic, S. M. (2023). Molecular characteristics of cisplatin-induced ototoxicity and therapeutic interventions. *International Journal of Molecular Sciences, 24*(22), Article 16545. <https://doi.org/10.3390/ijms242216545>
- Review of molecular pathways (uptake, oxidative stress, inflammation, cell death) and therapeutic targets. PMID [38003734](https://pubmed.ncbi.nlm.nih.gov/38003734/) · [PMC10671929](https://pmc.ncbi.nlm.nih.gov/articles/PMC10671929/)

**Cisplatin: Clinical Cohorts in Adults**

- Burger, A. V. M., Duinkerken, C. W., Theunissen, E. A. R., Schaeffers, A. W. M. A., Hauptmann, M., Hoetink, A. E., Balm, A. J. M., de Boer, J. P., Maas-Bannink, E., Exterkate, L., Slingerland, M., Jansen, J. C., Stokroos, R. J., de Bree, R., Devriese, L. A., Dreschler, W. A., Bruintjes, T. D., van Sluis, K. E., & Zuur, C. L. (2026). A prospective multicenter observational study investigating the concordance between patient-reported hearing loss and commonly used ototoxicity grading systems in patients treated with platinum-based chemotherapy. *Annals of Otology, Rhinology & Laryngology, 135*(6), 443–452. <https://doi.org/10.1177/00034894251408705>
- Concordance between patient-reported hearing loss and common ototoxicity grading systems. PMID [41549346](https://pubmed.ncbi.nlm.nih.gov/41549346/)
- Burger, A. V. M., Duinkerken, C. W., van Sluis, K. E., de Boer, J. P., Navran, A., Lanting, C. P., Jóźwiak, K., Dreschler, W. A., Balm, A. J. M., & Zuur, C. L. (2024). Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer. *European Archives of Oto-Rhino-Laryngology, 281*(12), 6627–6635. <https://doi.org/10.1007/s00405-024-08880-x>
- Head and neck chemoradiation: weekly vs. triweekly cisplatin and treatment-related hearing loss. PMID [39242413](https://pubmed.ncbi.nlm.nih.gov/39242413/) · [PMC11564257](https://pmc.ncbi.nlm.nih.gov/articles/PMC11564257/)
- Burger, A. V. M., Koot, M. A., van Balen, D. E. M., Schaeffers, A. W. M. A., Zuur, C. L., Devriese, L. A., Ridder, M., Hoetink, A. E., Schutte, T., & Crul, M. (2025). Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation. *Oral Oncology, 164*, Article 107246. <https://doi.org/10.1016/j.oraloncology.2025.107246>
- Head and neck chemoradiation: infusion duration and hydration schedules vs. hearing loss. PMID [40233546](https://pubmed.ncbi.nlm.nih.gov/40233546/)
- Garcia, S. L., Lauritsen, J., Christiansen, B. K., Hansen, I. F., Bandak, M., Dalgaard, M. D., Daugaard, G., & Gupta, R. (2023). Predicting hearing loss in testicular cancer patients after cisplatin-based chemotherapy. *Cancers, 15*(15), Article 3923. <https://doi.org/10.3390/cancers15153923>
- Prediction modeling of hearing loss in testicular cancer patients after cisplatin. PMID [37568739](https://pubmed.ncbi.nlm.nih.gov/37568739/) · [PMC10417151](https://pmc.ncbi.nlm.nih.gov/articles/PMC10417151/)
- Paken, J., Govender, C. D., Pillay, M., & Sewram, V. (2022). Cisplatin-associated ototoxicity: Perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting. *BMC Health Services Research, 22*(1), Article 791. <https://doi.org/10.1186/s12913-022-08099-8>
- Cervical cancer cohort (South Africa); implications for ototoxicity monitoring programs in public health settings. PMID [35717191](https://pubmed.ncbi.nlm.nih.gov/35717191/) · [PMC9206275](https://pmc.ncbi.nlm.nih.gov/articles/PMC9206275/)
- Sanchez, V. A., Dinh, P. C., Jr., Monahan, P. O., Althouse, S., Rooker, J., Sesso, H. D., Dolan, M. E., Weinzerl, M., Feldman, D. R., Fung, C., Einhorn, L. H., Frisina, R. D., & Travis, L. B. (2024). Comprehensive audiologic analyses after cisplatin-based chemotherapy. *JAMA Oncology, 10*(7), 912–922. <https://doi.org/10.1001/jamaoncol.2024.1233>
- Platinum Study: comprehensive audiologic testing (including speech-in-noise) in 100 survivors; risk factors for poorer outcomes and progression. PMID [38842797](https://pubmed.ncbi.nlm.nih.gov/38842797/) · [PMC11157440](https://pmc.ncbi.nlm.nih.gov/articles/PMC11157440/)
- Sanchez, V. A., Dinh, P. C., Jr., Monahan, P. O., Fung, C., Althouse, S., Stump, T., Rooker, J., Dolan, M. E., Feldman, D. R., Hamilton, R. J., Pierorazio, P. M., Martin, N. E., Huddart, R., Kollmannsberger, C., Root, J., Sesso, H. D., Weinzierl, M., Einhorn, L. H., Frisina, R. D., & Travis, L. B. (2026). Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from the Platinum Study: A multicentre cohort study. *eClinicalMedicine, 94*, Article 103841. <https://doi.org/10.1016/j.eclinm.2026.103841>
- Platinum Study: >1,400 adult-onset survivors; cumulative dose, renal function, and other risk factors for audiometric ototoxicity. PMID [41969333](https://pubmed.ncbi.nlm.nih.gov/41969333/) · [PMC13068843](https://pmc.ncbi.nlm.nih.gov/articles/PMC13068843/)
- Sanchez, V. A., Shuey, M. M., Dinh, P. C., Jr., Monahan, P. O., Fosså, S. D., Sesso, H. D., Dolan, M. E., Einhorn, L. H., Vaughn, D. J., Martin, N. E., Feldman, D. R., Kroenke, K., Fung, C., Frisina, R. D., & Travis, L. B. (2023). Patient-reported functional impairment due to hearing loss and tinnitus after cisplatin-based chemotherapy. *Journal of Clinical Oncology, 41*(12), 2211–2226. <https://doi.org/10.1200/JCO.22.01456>
- Platinum Study: patient-reported functional hearing and tinnitus impairment in testicular cancer survivors. PMID [36626694](https://pubmed.ncbi.nlm.nih.gov/36626694/) · [PMC10489421](https://pmc.ncbi.nlm.nih.gov/articles/PMC10489421/)
- Van Der Biest, H., Verhulst, S., Keppler, H., Maes, L., Acke, F., Saerens, M., Naert, E., Rottey, S., & Dhooge, I. (2026). Longitudinal audiological and vestibular follow-up in adult cancer patients receiving platinum-based chemotherapy. *Journal of the Association for Research in Otolaryngology, 27*(5), 823–842. <https://doi.org/10.1007/s10162-026-01062-y>
- Longitudinal audiologic and vestibular follow-up in adults receiving platinum chemotherapy. PMID [42443713](https://pubmed.ncbi.nlm.nih.gov/42443713/) · [PMC13687480](https://pmc.ncbi.nlm.nih.gov/articles/PMC13687480/)

**Cisplatin: Clinical Cohorts in Children**

- Attar, M., Alqarni, M. S., Alsinnari, Y. M., Bukhari, Z. M., Alshegifi, H., Alzhrani, A., Alshaikh, K., Alsubaie, H., Muqat, M., Alhakami, H., & Algarni, M. (2022). The incidence and risk factors of cisplatin and carboplatin ototoxicity in pediatric oncology patients at tertiary oncology center. *Indian Journal of Surgical Oncology, 13*(4), 925–930. <https://doi.org/10.1007/s13193-022-01579-7>
- Incidence and risk factors for cisplatin and carboplatin ototoxicity in a pediatric oncology center. PMID [36687225](https://pubmed.ncbi.nlm.nih.gov/36687225/) · [PMC9845443](https://pmc.ncbi.nlm.nih.gov/articles/PMC9845443/)
- Meijer, A. J. M., Li, K. H., Brooks, B., Clemens, E., Ross, C. J., Rassekh, S. R., Hoetink, A. E., van Grotel, M., van den Heuvel-Eibrink, M. M., & Carleton, B. C. (2022). The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. *Cancer, 128*(1), 169–179. <https://doi.org/10.1002/cncr.33848>
- Cumulative incidence of cisplatin hearing loss is higher and earlier in young children (2,052 audiologic assessments). PMID [34490624](https://pubmed.ncbi.nlm.nih.gov/34490624/)
- Romano, A., Rivetti, S., Brigato, F., Mastrangelo, S., Attinà, G., Maurizi, P., Galli, J., Fetoni, A. R., & Ruggiero, A. (2023). Early and long-term ototoxicity noted in children due to platinum compounds: Prevalence and risk factors. *Biomedicines, 11*(2), Article 261. <https://doi.org/10.3390/biomedicines11020261>
- Early and long-term pediatric platinum ototoxicity: prevalence and risk factors (SIOP Boston scale). PMID [36830798](https://pubmed.ncbi.nlm.nih.gov/36830798/) · [PMC9953080](https://pmc.ncbi.nlm.nih.gov/articles/PMC9953080/)
- Sherief, L. M., Rifky, E., Attia, M., Ahmed, R., Kamal, N. M., Oshi, M. A. M., & Hanna, D. (2022). Platinum-induced ototoxicity in pediatric cancer survivors: GSTP1 c.313A>G variant association. *Medicine, 101*(45), Article e31627. <https://doi.org/10.1097/MD.0000000000031627>
- Pediatric survivors of platinum therapy; GSTP1 variant association. PMID [36397425](https://pubmed.ncbi.nlm.nih.gov/36397425/) · [PMC9666226](https://pmc.ncbi.nlm.nih.gov/articles/PMC9666226/)
- Strebel, S., Mader, L., Sláma, T., Waespe, N., Weiss, A., Parfitt, R., Am Zehnhoff-Dinnesen, A., Kompis, M., von der Weid, N. X., Ansari, M., & Kuehni, C. E. (2022). Severity of hearing loss after platinum chemotherapy in childhood cancer survivors. *Pediatric Blood & Cancer, 69*(9), Article e29755. <https://doi.org/10.1002/pbc.29755>
- Swiss Childhood Cancer Survivor cohort: severity of hearing loss after platinum chemotherapy. PMID [35723448](https://pubmed.ncbi.nlm.nih.gov/35723448/)

**Carboplatin**

- Chawla, A., Carter, S., Wood, A., Staffieri, S., Dodgshun, A., Eisenstat, D. D., & Sullivan, M. (2026). Incidence and severity of carboplatin-associated hearing loss in children with cancer assessed by the SIOP Boston 2012 ototoxicity criteria. *Pediatric Blood & Cancer, 73*(9), Article e70494. <https://doi.org/10.1002/1545-5017.70494>
- Carboplatin without cisplatin in 200 children: SIOP Boston grade 2 or higher in 4.5%; younger age the main predictor. PMID [42504125](https://pubmed.ncbi.nlm.nih.gov/42504125/)
- Davis, M. E., Guarini, E., O'Connor, K., Francis, J. H., & Abramson, D. H. (2025). Hearing evaluations in children with retinoblastoma treated with intra-arterial carboplatin chemotherapy: A single institution review. *Journal of Pediatric Ophthalmology and Strabismus, 62*(1), 27–32. <https://doi.org/10.3928/01913913-20240807-02>
- Retinoblastoma: hearing evaluations after intra-arterial carboplatin. PMID [39254185](https://pubmed.ncbi.nlm.nih.gov/39254185/) · [PMC11757066](https://pmc.ncbi.nlm.nih.gov/articles/PMC11757066/)
- Funt, S. A., Knezevic, A., Wilson, K., Bromberg, M., Budnick, A., O'Connor, K. L., McHugh, D. J., Larsen, E., Bajorin, D. F., Motzer, R. J., Tonorezos, E. S., Patil, S., & Feldman, D. R. (2023). Ototoxicity associated with high-dose carboplatin for patients with previously treated germ cell tumors. *Cancer, 129*(24), 3952–3961. <https://doi.org/10.1002/cncr.34991>
- High-dose carboplatin for previously treated germ cell tumors in adults: ototoxicity outcomes. PMID [37715631](https://pubmed.ncbi.nlm.nih.gov/37715631/) · [PMC11305123](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305123/)
- Jiménez-Labaig, P., Mirallas, O., Pereira, F., Sanz, J., Felip, E., Rodon, J., Colombo, N., Galsky, M. D., & Harrington, K. J. (2026). Reappraisal of cisplatin vs carboplatin treatment for solid tumors: An umbrella meta-analysis. *JAMA Network Open, 9*(9), Article e2634287. <https://doi.org/10.1001/jamanetworkopen.2026.34287>
- Umbrella meta-analysis comparing cisplatin vs. carboplatin efficacy and toxicity across solid tumors. PMID [42752909](https://pubmed.ncbi.nlm.nih.gov/42752909/) · [PMC13586887](https://pmc.ncbi.nlm.nih.gov/articles/PMC13586887/)
- Singh, V., Banumathy, N., Palla, S., Singh, U., Setia, M., Aggarwal, B., Trehan, A., & Bansal, D. (2025). Carboplatin-induced ototoxicity in children treated for retinoblastoma. *Pediatric Blood & Cancer, 72*(10), Article e31934. <https://doi.org/10.1002/pbc.31934>
- Retinoblastoma survivors: extended high-frequency hearing loss after carboplatin. PMID [40682276](https://pubmed.ncbi.nlm.nih.gov/40682276/)
- Spence, A., Camet, M., Hayashi, S. S., McGlynn, M. C., Wu, N., & Hayashi, R. J. (2025). Ototoxicity in pediatric hematopoietic stem cell transplantation with high-dose carboplatin: Identifying modifiable risk factors through the inclusion of younger patients. *Pediatric Blood & Cancer, 72*(10), Article e31926. <https://doi.org/10.1002/pbc.31926>
- High-dose carboplatin in pediatric stem cell transplant: modifiable risk factors. PMID [40685565](https://pubmed.ncbi.nlm.nih.gov/40685565/)

**Pharmacogenomics and Risk Prediction**

- Duinkerken, C. W., Chiodo, S., Hueniken, K., Hauptmann, M., Jóźwiak, K., Cheng, D., Hope, A., Liu, G., & Zuur, C. L. (2024). The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy. *Cancer Medicine, 13*(16), Article e7465. <https://doi.org/10.1002/cam4.7465>
- Genetic variants for predicting hearing loss after cisplatin chemoradiotherapy. PMID [39159054](https://pubmed.ncbi.nlm.nih.gov/39159054/) · [PMC11332395](https://pmc.ncbi.nlm.nih.gov/articles/PMC11332395/)
- Hurkmans, E. G. E., Klumpers, M. J., Dello Russo, C., De Witte, W., Guchelaar, H. J., Gelderblom, H., Cleton-Jansen, A. M., Vermeulen, S. H., Kaal, S., van der Graaf, W. T. A., Flucke, U., Gidding, C. E. M., Schreuder, H. W. B., de Bont, E. S. J. M., Caron, H. N., Gattuso, G., Schiavello, E., Terenziani, M., Massimino, M., . . . Te Loo, D. M. W. M. (2022). Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia. *Frontiers in Pharmacology, 13*, Article 980309. <https://doi.org/10.3389/fphar.2022.980309>
- Genome-wide analyses of platinum ototoxicity in children (GO-CAT and UK MAGIC consortia). PMID [36699085](https://pubmed.ncbi.nlm.nih.gov/36699085/) · [PMC9870026](https://pmc.ncbi.nlm.nih.gov/articles/PMC9870026/)
- Lazetic, T., Miao, D. N. R., Drögemöller, B. I., Dabdoub, A., & Abitbol, J. M. (2026). Navigating the genetic risk of chemotherapy-induced hearing loss in the stria vascularis. *Clinical Pharmacology & Therapeutics, 119*(4), 846–858. <https://doi.org/10.1002/cpt.70160>
- Review of genetic risk in the stria vascularis. PMID [41346314](https://pubmed.ncbi.nlm.nih.gov/41346314/) · [PMC12997515](https://pmc.ncbi.nlm.nih.gov/articles/PMC12997515/)
- Miao, D. N. R., Wilke, M. A. P., Pham, J., Ladha, F., Singh, M., Arsenio, J., Luca, E., Dabdoub, A., Yang, W., Yang, J. J., & Drögemöller, B. I. (2024). Leveraging large-scale datasets and single cell omics data to develop a polygenic score for cisplatin-induced ototoxicity. *Human Genomics, 18*(1), Article 112. <https://doi.org/10.1186/s40246-024-00679-5>
- Polygenic score development for cisplatin ototoxicity. PMID [39380081](https://pubmed.ncbi.nlm.nih.gov/39380081/) · [PMC11463131](https://pmc.ncbi.nlm.nih.gov/articles/PMC11463131/)
- Scott, E. N., Joseph, A. A., Dhanda, A., Tanoshima, R., Brooks, B., Rassekh, S. R., Ross, C. J. D., Carleton, B. C., & Loucks, C. M. (2023). Systematic critical review of genetic factors associated with cisplatin-induced ototoxicity: Canadian Pharmacogenomics Network for Drug Safety 2022 update. *Therapeutic Drug Monitoring, 45*(6), 714–730. <https://doi.org/10.1097/FTD.0000000000001113>
- Canadian Pharmacogenomics Network for Drug Safety 2022 systematic critical review of genetic risk factors. PMID [37726872](https://pubmed.ncbi.nlm.nih.gov/37726872/)
- Shahbazi, M., Wheeler, H. E., Zhang, X., Frisina, R. D., Travis, L. B., & Dolan, M. E. (2025). Comparison of associations suggests mainly distinct pools of genetic risk factors contribute to cisplatin-induced hearing loss and hearing difficulty in the general population. *Frontiers in Pharmacology, 16*, Article 1577072. <https://doi.org/10.3389/fphar.2025.1577072>
- Compares genetic risk for cisplatin hearing loss with hearing difficulty in the general population. PMID [40932864](https://pubmed.ncbi.nlm.nih.gov/40932864/) · [PMC12417478](https://pmc.ncbi.nlm.nih.gov/articles/PMC12417478/)
- Zhang, X., Trendowski, M. R., Wilkinson, E., Shahbazi, M., Dinh, P. C., Shuey, M. M., Regeneron Genetics Center, Feldman, D. R., Hamilton, R. J., Vaughn, D. J., Fung, C., Kollmannsberger, C., Huddart, R., Martin, N. E., Sanchez, V. A., Frisina, R. D., Einhorn, L. H., Cox, N. J., Travis, L. B., & Dolan, M. E. (2022). Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. *Cancer Medicine, 11*(14), 2801–2816. <https://doi.org/10.1002/cam4.4644>
- Pharmacogenomics of cisplatin hearing loss, tinnitus, and neuropathy (GWAS, 1,680 survivors). PMID [35322580](https://pubmed.ncbi.nlm.nih.gov/35322580/) · [PMC9302309](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302309/)

**Otoprotection: Sodium Thiosulfate**

- Dubashynskaya, N. V., Borovskoy, A. Y., Zhuravskii, S. G., & Skorik, Y. A. (2026). Advanced delivery systems for sodium thiosulfate in cisplatin otoprotection. *European Journal of Pharmaceutics and Biopharmaceutics, 227*, Article 115183. <https://doi.org/10.1016/j.ejpb.2026.115183>
- Review of advanced delivery systems for sodium thiosulfate. PMID [42437593](https://pubmed.ncbi.nlm.nih.gov/42437593/)
- Kallenberger, E. M., Briggs, E. E., Nguyen, S. A., Dixon, P. R., Drawdy, A. V., Labadie, R. F., Meyer, T. A., & White, D. R. (2025). Preventing hearing loss in children receiving cisplatin: A systematic review and meta-analysis. *The Laryngoscope, 135*(8), 2662–2669. <https://doi.org/10.1002/lary.32158>
- Systematic review and meta-analysis of hearing-loss prevention in children receiving cisplatin. PMID [40165641](https://pubmed.ncbi.nlm.nih.gov/40165641/)
- Meijer, A. J. M., Diepstraten, F. A., Ansari, M., Bouffet, E., Bleyer, A., Fresneau, B., Geller, J. I., Huitema, A. D. R., Kogner, P., Maibach, R., O'Neill, A. F., Papadakis, V., Rajput, K. M., Veal, G. J., Sullivan, M., van den Heuvel-Eibrink, M. M., & Brock, P. R. (2024). Use of sodium thiosulfate as an otoprotectant in patients with cancer treated with platinum compounds: A review of the literature. *Journal of Clinical Oncology, 42*(18), 2219–2232. <https://doi.org/10.1200/JCO.23.02353>
- Comprehensive review of systemic and local sodium thiosulfate in children and adults; timing and dosing considerations. PMID [38648563](https://pubmed.ncbi.nlm.nih.gov/38648563/) · [PMC11191063](https://pmc.ncbi.nlm.nih.gov/articles/PMC11191063/)
- Ohlsen, T. J. D., Collier, W. H., Ramdas, J., Sung, L., & Freyer, D. R. (2025). Otoprotective effects of sodium thiosulfate by demographic and clinical characteristics: A report from Children's Oncology Group study ACCL0431. *Pediatric Blood & Cancer, 72*(3), Article e31479. <https://doi.org/10.1002/pbc.31479>
- ACCL0431: sodium thiosulfate effect by demographic and clinical subgroups. PMID [39654065](https://pubmed.ncbi.nlm.nih.gov/39654065/) · [PMC11786791](https://pmc.ncbi.nlm.nih.gov/articles/PMC11786791/)
- Orgel, E., Knight, K. R., Villaluna, D., Krailo, M., Esbenshade, A. J., Sung, L., & Freyer, D. R. (2023). Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology ototoxicity scale: A report from the Children's Oncology Group study ACCL0431. *Pediatric Blood & Cancer*. Advance online publication. <https://doi.org/10.1002/pbc.30550>
- ACCL0431 reanalysis using the SIOP ototoxicity scale. PMID [37416942](https://pubmed.ncbi.nlm.nih.gov/37416942/) · [PMC10771531](https://pmc.ncbi.nlm.nih.gov/articles/PMC10771531/)
- Vittayakoonsakulchai, K., Pitathawatchai, P., Plodpai, Y., Atchariyasathian, V., Khaimook, W., Kirtsreesakul, V., Kittichet, R., & Prayuenyong, P. (2026). Efficacy of intratympanic sodium thiosulfate gel injection to prevent cisplatin-induced ototoxicity. *The Laryngoscope*. Advance online publication. <https://doi.org/10.1002/lary.71028>
- RCT of intratympanic sodium thiosulfate gel in adults with head and neck cancer. PMID [42971568](https://pubmed.ncbi.nlm.nih.gov/42971568/)

**Otoprotection: Other Agents and Local Delivery**

- Alzahrani, M., Almalki, Z. A., Alqahtani, S., Alnemari, F. S., Alghamdi, F. S., & Aljuaid, S. O. (2026). Intratympanic steroid regimen for prevention of cisplatin-induced hearing loss: A systematic review. *Audiology and Neurotology*. Advance online publication. <https://doi.org/10.1159/aud/abnag002>
- Systematic review: no consistent benefit of intratympanic steroids. PMID [42555534](https://pubmed.ncbi.nlm.nih.gov/42555534/)
- Briggs, E. E., Kallenberger, E. M., Nguyen, S. A., Dixon, P. R., Drawdy, A. V., Kejner, A. E., Kaczmar, J. M., Newman, J. G., & Albergotti, W. G. (2025). Preventing cisplatin-induced hearing loss in adults: A systematic review and meta-analysis. *Otology & Neurotology, 46*(4), 351–357. <https://doi.org/10.1097/MAO.0000000000004446>
- Systematic review and meta-analysis of hearing-loss prevention in adults (8 studies, N=431). PMID [39965236](https://pubmed.ncbi.nlm.nih.gov/39965236/)
- Correa-Morales, J. E., Giraldo-Moreno, S., Mantilla-Manosalva, N., Cuellar-Valencia, L., Borja-Montes, O. F., Bedoya-Muñoz, L. J., Iriarte-Aristizábal, M. F., Quintero-Muñoz, E., & Zuluaga-Liberato, A. M. (2024). Prevention and treatment of cisplatin-induced ototoxicity in adults: A systematic review. *Clinical Otolaryngology, 49*(1), 1–15. <https://doi.org/10.1111/coa.14106>
- Systematic review of prevention and treatment of cisplatin ototoxicity in adults. PMID [37818931](https://pubmed.ncbi.nlm.nih.gov/37818931/)
- Masroor, A., Streefkerk, N., Van Grotel, M., Geller, J. I., Ansari, M., Bouffet, E., Bleyer, A., Fresneau, B., Sullivan, M., Knight, K., Kogner, P., Maibach, R., O'neill, A. F., Papadakis, V., Rajput, K. M., Brock, P. R., Veal, G. J., Hoetink, A. E., Huitema, A. D. R., & Van Den Heuvel-Eibrink, M. M. (2026). Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: A systematic review. *Drug Delivery, 33*(1), Article 2665892. <https://doi.org/10.1080/10717544.2026.2665892>
- Systematic review of locally applied otoprotectants other than sodium thiosulfate. PMID [42068011](https://pubmed.ncbi.nlm.nih.gov/42068011/) · [PMC13137753](https://pmc.ncbi.nlm.nih.gov/articles/PMC13137753/)
- Moreno, I., & Belinchon, A. (2026). Intratympanic dexamethasone efficacy in preventing cisplatin-induced tinnitus: A randomized controlled phase IIIB clinical trial. *Ear and Hearing, 47*(5), 1212–1218. <https://doi.org/10.1097/AUD.0000000000001818>
- Phase IIIB RCT of intratympanic dexamethasone for cisplatin-induced tinnitus. PMID [41940636](https://pubmed.ncbi.nlm.nih.gov/41940636/)
- Panizza, B. J., O'Leary, S. J., Hart, C. D., Diwakarla, C. S., Barnett, C., Lapuerta, P., Lee, J., Raines, S., Quigley, T., Wolff, H. M., Keilty, J., Ladwa, R., Porceddu, S. V., McGrath, M., Seetharamu, N., Fua, T., & Rischin, D. (2025). Randomized phase Ib clinical trial of DB-020 intratympanic injections to reduce high-dose cisplatin ototoxicity. *Journal of Clinical Oncology, 43*(19), 2155–2163. <https://doi.org/10.1200/JCO.24.00905>
- Phase Ib RCT of DB-020 intratympanic injections with high-dose cisplatin. PMID [40403227](https://pubmed.ncbi.nlm.nih.gov/40403227/) · [PMC12199801](https://pmc.ncbi.nlm.nih.gov/articles/PMC12199801/)

**Monitoring, Grading, and Service Delivery**

- Ehlert, K., Heinze, B., Graham, M. A., & Swanepoel, D. (2023). Surveillance for ototoxicity in platinum-based chemotherapy using mobile health audiometry with extended high frequencies. *The Journal of Laryngology & Otology, 137*(1), 61–67. <https://doi.org/10.1017/S0022215122001281>
- Mobile health audiometry with extended high frequencies for ototoxicity surveillance. PMID [35611593](https://pubmed.ncbi.nlm.nih.gov/35611593/) · [PMC9834705](https://pmc.ncbi.nlm.nih.gov/articles/PMC9834705/)
- Lee, D. S., Mueller, L., Wong, S. K., Travis, E. Y., Munyemana, M. A., Mazul, A. L., McClannahan, K. S., Jeffe, D. B., & Lieu, J. E. (2026). Survivors' perspectives on cisplatin-induced ototoxicity and barriers to ototoxicity monitoring. *Journal of Cancer Survivorship, 20*(Suppl 1), 741–751. <https://doi.org/10.1007/s11764-025-01860-y>
- Survivor perspectives on ototoxicity and barriers to monitoring. PMID [40601160](https://pubmed.ncbi.nlm.nih.gov/40601160/) · [PMC12434416](https://pmc.ncbi.nlm.nih.gov/articles/PMC12434416/)
- Lee, D. S., Travis, E. Y., Wong, S. K., Munyemana, M. A., Mueller, L., Rowling, C. C., Rich, J. T., Pipkorn, P., Puram, S. V., Jackson, R. S., Adkins, D. R., Oppelt, P., Thorstad, W. L., Wick, C. C., Zevallos, J. P., McClannahan, K., & Mazul, A. L. (2025). Trends in ototoxicity monitoring among cisplatin-treated patients with cancer. *Journal of Cancer Survivorship, 19*(5), 1750–1760. <https://doi.org/10.1007/s11764-024-01586-3>
- Patterns and barriers in ototoxicity monitoring among adults treated with cisplatin. PMID [38630333](https://pubmed.ncbi.nlm.nih.gov/38630333/)
- Patel, J., Beiriger, J., Liu, K., Urdang, Z., Croce, J., Wolfson, M., Hulswit, J., Giglio, O., Hunter, J. B., & Middleton, I. (2025). Ototoxicity monitoring: The evolution of a protocol for head and neck cancer patients. *OTO Open, 9*(2), Article e70070. <https://doi.org/10.1002/oto2.70070>
- Development and evaluation of a head and neck cancer ototoxicity monitoring program. PMID [40196215](https://pubmed.ncbi.nlm.nih.gov/40196215/) · [PMC11973582](https://pmc.ncbi.nlm.nih.gov/articles/PMC11973582/)

**Foundational Papers, 2020–2021**

- Chen, C. H., Huang, C. Y., Lin, H. H., Wang, M. C., Chang, C. Y., & Cheng, Y. F. (2021). Association of sodium thiosulfate with risk of ototoxic effects from platinum-based chemotherapy: A systematic review and meta-analysis. *JAMA Network Open, 4*(8), Article e2118895. <https://doi.org/10.1001/jamanetworkopen.2021.18895>
- Systematic review and meta-analysis of sodium thiosulfate and platinum-related ototoxicity. PMID [34338793](https://pubmed.ncbi.nlm.nih.gov/34338793/) · [PMC8329743](https://pmc.ncbi.nlm.nih.gov/articles/PMC8329743/)
- Das, N., Kaushal, D., Patro, S. K., Pareek, P., Dixit, A., Soni, K., Prakasan Nair, N., Choudhury, B., & Goyal, A. (2021). Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. *Acta Oto-Laryngologica, 141*(9), 885–893. <https://doi.org/10.1080/00016489.2021.1969036>
- Relative contributions of radiation and cisplatin to hearing loss in head and neck cancer. PMID [34486907](https://pubmed.ncbi.nlm.nih.gov/34486907/)
- Duinkerken, C. W., de Weger, V. A., Dreschler, W. A., van der Molen, L., Pluim, D., Rosing, H., Nuijen, B., Hauptmann, M., Beijnen, J. H., Balm, A. J. M., de Boer, J. P., Burgers, J. A., Marchetti, S., Schellens, J. H. M., & Zuur, C. L. (2021). Transtympanic sodium thiosulfate for prevention of cisplatin-induced ototoxicity: A randomized clinical trial. *Otology & Neurotology, 42*(5), 678–685. <https://doi.org/10.1097/MAO.0000000000003069>
- RCT of transtympanic sodium thiosulfate against cisplatin hearing loss. PMID [33710154](https://pubmed.ncbi.nlm.nih.gov/33710154/)
- Freyer, D. R., Brock, P. R., Chang, K. W., Dupuis, L. L., Epelman, S., Knight, K., Mills, D., Phillips, R., Potter, E., Risby, D., Simpkin, P., Sullivan, M., Cabral, S., Robinson, P. D., & Sung, L. (2020). Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: A clinical practice guideline. *The Lancet Child & Adolescent Health, 4*(2), 141–150. <https://doi.org/10.1016/S2352-4642(19)30336-0>
- International clinical practice guideline on preventing cisplatin ototoxicity in children and adolescents (sodium thiosulfate, amifostine, intratympanic therapy, infusion duration). PMID [31866182](https://pubmed.ncbi.nlm.nih.gov/31866182/) · [PMC7521149](https://pmc.ncbi.nlm.nih.gov/articles/PMC7521149/)
- Gertson, K., Hayashi, S. S., Trinkaus, K., Wan, F., & Hayashi, R. J. (2020). Prevalence of ototoxicity following hematopoietic stem cell transplantation in pediatric patients. *Biology of Blood and Marrow Transplantation, 26*(1), 107–113. <https://doi.org/10.1016/j.bbmt.2019.08.028>
- Ototoxicity after pediatric hematopoietic stem cell transplantation (high-dose carboplatin context). PMID [31494228](https://pubmed.ncbi.nlm.nih.gov/31494228/) · [PMC7135908](https://pmc.ncbi.nlm.nih.gov/articles/PMC7135908/)
- Meijer, A. J. M., Diepstraten, F. A., Langer, T., Broer, L., Domingo, I. K., Clemens, E., Uitterlinden, A. G., de Vries, A. C. H., van Grotel, M., Vermeij, W. P., Ozinga, R. A., Binder, H., Byrne, J., van Dulmen-den Broeder, E., Garrè, M. L., Grabow, D., Kaatsch, P., Kaiser, M., Kenborg, L., . . . CPNDS Consortium (2021). TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. *npj Precision Oncology, 5*(1), Article 64. <https://doi.org/10.1038/s41698-021-00178-z>
- PanCareLIFE: TCERG1L variation and cisplatin hearing loss in childhood cancer. PMID [34262104](https://pubmed.ncbi.nlm.nih.gov/34262104/) · [PMC8280110](https://pmc.ncbi.nlm.nih.gov/articles/PMC8280110/)
- Mukherjea, D., Dhukhwa, A., Sapra, A., Bhandari, P., Woolford, K., Franke, J., Ramkumar, V., & Rybak, L. (2020). Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity. *Expert Opinion on Drug Metabolism & Toxicology, 16*(10), 965–982. <https://doi.org/10.1080/17425255.2020.1806235>
- Review of strategies to reduce platinum-induced ototoxicity. PMID [32757852](https://pubmed.ncbi.nlm.nih.gov/32757852/) · [PMC7606369](https://pmc.ncbi.nlm.nih.gov/articles/PMC7606369/)
- Paken, J., Govender, C. D., Pillay, M., Ayele, B. T., & Sewram, V. (2021). Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa. *BMC Cancer, 21*(1), Article 822. <https://doi.org/10.1186/s12885-021-08567-0>
- Prospective cohort of cisplatin ototoxicity in cervical cancer patients (South Africa). PMID [34271863](https://pubmed.ncbi.nlm.nih.gov/34271863/) · [PMC8285889](https://pmc.ncbi.nlm.nih.gov/articles/PMC8285889/)
- Prayuenyong, P., Baguley, D. M., Kros, C. J., & Steyger, P. S. (2021). Preferential cochleotoxicity of cisplatin. *Frontiers in Neuroscience, 15*, Article 695268. <https://doi.org/10.3389/fnins.2021.695268>
- Review of why cisplatin preferentially damages the cochlea rather than the vestibular system. PMID [34381329](https://pubmed.ncbi.nlm.nih.gov/34381329/) · [PMC8350121](https://pmc.ncbi.nlm.nih.gov/articles/PMC8350121/)
- Romano, A., Capozza, M. A., Mastrangelo, S., Maurizi, P., Triarico, S., Rolesi, R., Attinà, G., Fetoni, A. R., & Ruggiero, A. (2020). Assessment and management of platinum-related ototoxicity in children treated for cancer. *Cancers, 12*(5), Article 1266. <https://doi.org/10.3390/cancers12051266>
- Review of assessment, grading, and management of platinum ototoxicity in children. PMID [32429551](https://pubmed.ncbi.nlm.nih.gov/32429551/) · [PMC7281210](https://pmc.ncbi.nlm.nih.gov/articles/PMC7281210/)
- Santucci, N. M., Garber, B., Ivory, R., Kuhn, M. A., Stephen, M., & Aizenberg, D. (2021). Insight into the current practice of ototoxicity monitoring during cisplatin therapy. *Journal of Otolaryngology - Head & Neck Surgery, 50*(1), Article 19. <https://doi.org/10.1186/s40463-021-00506-0>
- Current practice of ototoxicity monitoring during cisplatin therapy. PMID [33766142](https://pubmed.ncbi.nlm.nih.gov/33766142/) · [PMC7995701](https://pmc.ncbi.nlm.nih.gov/articles/PMC7995701/)
- Steyger, P. S. (2021). Mechanisms of aminoglycoside- and cisplatin-induced ototoxicity. *American Journal of Audiology, 30*(3S), 887–900. [https://doi.org/10.1044/2021\_AJA-21-00006](https://doi.org/10.1044/2021_AJA-21-00006)
- Review of aminoglycoside and cisplatin ototoxicity mechanisms. PMID [34415784](https://pubmed.ncbi.nlm.nih.gov/34415784/) · [PMC9126111](https://pmc.ncbi.nlm.nih.gov/articles/PMC9126111/)
- Trendowski, M. R., Wheeler, H. E., El-Charif, O., Feldman, D. R., Hamilton, R. J., Vaughn, D. J., Fung, C., Kollmannsberger, C., Einhorn, L. H., Travis, L. B., & Dolan, M. E. (2020). Clinical and genome-wide analysis of multiple severe cisplatin-induced neurotoxicities in adult-onset cancer survivors. *Clinical Cancer Research, 26*(24), 6550–6558. <https://doi.org/10.1158/1078-0432.CCR-20-2682>
- Clinical and genome-wide analysis of severe cisplatin neurotoxicities, including hearing loss, in adult-onset survivors. PMID [32998964](https://pubmed.ncbi.nlm.nih.gov/32998964/) · [PMC7744329](https://pmc.ncbi.nlm.nih.gov/articles/PMC7744329/)
- Viglietta, V., Shi, F., Hu, Q. Y., Ren, Y., Keilty, J., Wolff, H., McCarthy, R., Kropp, J., Weber, P., & Soglia, J. (2020). Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients. *Investigational New Drugs, 38*(5), 1463–1471. <https://doi.org/10.1007/s10637-020-00918-1>
- Phase 1 study of intratympanic thiosulfate in patients receiving cisplatin. PMID [32157599](https://pubmed.ncbi.nlm.nih.gov/32157599/) · [PMC7497691](https://pmc.ncbi.nlm.nih.gov/articles/PMC7497691/)
- Waissbluth, S. (2020). Clinical trials evaluating transtympanic otoprotectants for cisplatin-induced ototoxicity: What do we know so far? *European Archives of Oto-Rhino-Laryngology, 277*(9), 2413–2422. <https://doi.org/10.1007/s00405-020-06003-w>
- Review of clinical trials of transtympanic otoprotectants. PMID [32358651](https://pubmed.ncbi.nlm.nih.gov/32358651/)
- Yu, D., Gu, J., Chen, Y., Kang, W., Wang, X., & Wu, H. (2020). Current strategies to combat cisplatin-induced ototoxicity. *Frontiers in Pharmacology, 11*, Article 999. <https://doi.org/10.3389/fphar.2020.00999>
- Review of strategies to combat cisplatin ototoxicity, including otoprotectant trials. PMID [32719605](https://pubmed.ncbi.nlm.nih.gov/32719605/) · [PMC7350523](https://pmc.ncbi.nlm.nih.gov/articles/PMC7350523/)

**Landmark Sodium Thiosulfate Trials (2017–2018)**

- Brock, P. R., Maibach, R., Childs, M., Rajput, K., Roebuck, D., Sullivan, M. J., Laithier, V., Ronghe, M., Dall'Igna, P., Hiyama, E., Brichard, B., Skeen, J., Mateos, M. E., Capra, M., Rangaswami, A. A., Ansari, M., Rechnitzer, C., Veal, G. J., Covezzoli, A., . . . Neuwelt, E. A. (2018). Sodium thiosulfate for protection from cisplatin-induced hearing loss. *New England Journal of Medicine, 378*(25), 2376–2385. <https://doi.org/10.1056/NEJMoa1801109>
- SIOPEL-6: international randomized phase 3 trial in children with standard-risk hepatoblastoma receiving cisplatin alone, with sodium thiosulfate given 6 hours after cisplatin. Hearing loss (Brock grade 1 or higher) in 33% with sodium thiosulfate vs. 63% with cisplatin alone (n=101 assessable). PMID [29924955](https://pubmed.ncbi.nlm.nih.gov/29924955/) · [PMC6117111](https://pmc.ncbi.nlm.nih.gov/articles/PMC6117111/)
- Freyer, D. R., Chen, L., Krailo, M. D., Knight, K., Villaluna, D., Bliss, B., Pollock, B. H., Ramdas, J., Lange, B., Van Hoff, D., VanSoelen, M. L., Wiernikowski, J., Neuwelt, E. A., & Sung, L. (2017). Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): A multicentre, randomised, controlled, open-label, phase 3 trial. *The Lancet Oncology, 18*(1), 63–74. <https://doi.org/10.1016/S1470-2045(16)30625-8>
- ACCL0431 (Children's Oncology Group): multicenter, randomized, open-label phase 3 trial in children aged 1–18 with newly diagnosed cancer receiving cisplatin. Sodium thiosulfate 16 g/m2 given 6 hours after each cisplatin dose. Hearing loss (ASHA criteria) in 28.6% with sodium thiosulfate vs. 56.4% with observation (n=104 assessable; adjusted OR 0.31). Funded by the US National Cancer Institute. PMID [27914822](https://pubmed.ncbi.nlm.nih.gov/27914822/) · [PMC5520988](https://pmc.ncbi.nlm.nih.gov/articles/PMC5520988/)
